Levodopa Plus Occlusion Therapy versus Occlusion Therapy Alone for Children with Anisometropic Amblyopia
Purpose: This study aimed to compare the effects of short-term administration of levodopa plus occlusion therapy versus occlusion therapy alone in preschool children with hyperopic anisometropic amblyopia.
Methods: This comparative interventional study included 40 eligible preschool children aged 6 to 7 years with hyperopic anisometropic amblyopia. The primary outcome measure was the logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity recorded at baseline, 3 weeks after the treatment initiation and 12 weeks after the treatment termination. The results were compared between the two groups.
Results: No statistically significant intergroup difference was observed in baseline logMAR visual acuities (P = 0.92). The mean logMAR visual acuities of the amblyopic eyes were significantly better in both groups three weeks after the treatment initiation than the baseline (P < 0.01 in both groups). At 12 weeks after treatment termination, the logMAR visual acuities of the amblyopic eyes were significantly better than the baseline values (P < 0.001 in the placebo group and P = 0.09 in the levodopa group). Intergroup comparisons revealed no statistically significant difference in visual acuities 3 weeks after the treatment initiation (P = 0.11) and 12 weeks after the treatment termination (P = 0.10). Twelve weeks after the treatment termination, visual acuities regressed 0.037 logMAR in the placebo group and 0.042 logMAR in the levodopa group. These regression rates were not significantly different (P = 0.89).
Conclusion: The results of this study provide evidence that adding short-term administration of levodopa to occlusion therapy in hyperopic anisometropic amblyopia offers no additional benefit in visual outcomes and provides no advantage in terms of the regression rate.
Amblyopia, Anisometropic, Levodopa, Occlusion Therapy
1. von Noorden GK. Binocular vision and ocular motility: theory and practice of management of strabismus. 5th ed. Lous Mosby-Year Book: USA, St. Louis, Missouri 63146; 1996:216–254,512–520.
2. Keech RV. Practical management of amblyopia. In: Focal points: clinical modules for ophthalmologist. San Francisco, CA: American Academy of Ophthalmology; 2000:18.
3. Arruga A. Effect of occlusion of amblyopic eye on amblyopia and eccentric fixation. Trans Oph Soc UK 1962;82:45–49.
4. Leguire LE, Rogers GL, Bremer DL, Walson P, Hadjieonstantinou-Neff M. Levodopa and childhood amblyopia. J Pediatr Ophthalmol Strabismus 1992;29:290–298.
5. Leguire LE, Roger GL, Bremer DL, Walson PD, McGregor ML. Levodopa/carbidopa for childhood amblyopia. Invest Ophthalmol Vis Sci 1993;34:3090–3095.
6. Leguire LE, Walson PD, Rogers GL, Bremer DL, McGregor ML. Longitudinal study of levodopa/carbidopa for childhood amblyopia. J Pediatr Ophthalmol Strabismus 1993;30:354–360.
7. Gottlob I, Stangler-Zuschrott E. Effect of levodopa on contrast sensitivity and scotomas in human amblyopia. Invest Ophthalmol Vis Sci 1990;31:776–780.
8. Gottlob I, Charlier J, Reincoke RD. Visual acuities and scotomas after one week levodopa administration in human amblyopia. Invest Ophthalmol Vis Sci 1992;33:2722–2728.
9. Leguire LE, Walson PD, Rogers GL, Bremer DL, McGregor ML. Levodopa/carbidopa treatment for amblyopia in older children. J Pediatr Ophthalmol Strabismus 1995;32:143–151.
10. Leguire LE, Rogers GL, Walson PD, Bremer DL, McGregor ML. Occlusion and levodopa-carbidopa treatment for childhood amblyopia. J AAPOS 1998;2:257–264.
11. Leguire LE, Komaromy KL, Nairus TM, Rogers GL. Longterm follow-up of L-dopa treatment in children with amblyopia. J Pediatr Ophthalmol Strabismus 2002;39:326– 330;quiz 345–346.
12. Bhartiya P, Sharma P, Biswas NR, Tandon R, Khokhar SK. Levodopa-carbidopa with occlusion in older children with amblyopia. J AAPOS 2002;6:368–372.
13. Nguyen-Lergos J, Durand J, Simon A. Catecholamine cell types in the human retina. Clin Vis Sci 1992;7:435–447.
14. Algaze A, Leguire LE, Roberts C, Ibinson JW, Lewis JR, Rogers G. The effects of Ldopa on the functional magnetic resonance imaging response of patients with amblyopia: a pilot study. J AAPOS 2005;9:216–223.
15. Yang CI, Yang ML, Huang JC, Wan YL, Jui-Fang Tsai R, Wai YY, et al. Functional MRI of amblyopia before and after levodopa. Neurosci Lett 2003;339:49–52.
16. Yeh KC, August TF, Bush DF, Lasseter KC, Musson DG, Schwartz S, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989;39:25–38.
17. Bartholine G, Pletscher A. Cerebral accumulation and metabolism of 14C-dopa after selective inhibition of peripheral decarboxylase. J Pharmacol Exp Ther 1968;161:14–20.
18. Dadeya S, Vats P, Malik KP. Levodopa/carbidopa in the treatment of amblyopia. J Pediatr Ophthalmol Strabismus 2009;46:87–90;quiz 91–92.
19. Rashad MA. Pharmacological enhancement of treatment for amblyopia. Clin Ophthalmol 2012;6:409–416.
20. Repka MX, Kraker RT, Dean TW, Beck RW, Siatkowski RM, Holmes JM, et al. A randomized trial of levodopa as treatment for residual amblyopia in older children. Ophthalmology 2015;122:874–881.
21. Pandey PK, Chaudhuri Z, Kumar M, Satyabala K, Sharma P. Effect of levodopa and carbidopa in human amblyopia. J Pediatr Ophthalmol Strabismus 2002;39:81–89.
22. Mohan K, Dhankar V, Sharma A. Visual acuities after levodopa administration in amblyopia. J Pediatr Ophthalmol Strabismus 2001;38:62–67;quiz 96–97.
23. Dhall R, Kreitzman DL. Advances in levodopa therapy for Parkinson disease: review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology 2016;86:S13–S24.
24. Lee KE, Kang HS, Yu HJ, Roh SY. Thrombocytopenia associated with levodopa treatment. J Mov Disord 2013;6:21– 22.
25. Giner V, Rueda D, Salvador A, Hernández JC, Esteban MJ, Redón J. Thrombocytopenia associated with levodopa treatment. Arch Intern Med 2003;163:735–736.